[1] M. C. Kew, “Epidemiology of hepatocellular carcinoma,” Toxicology, vol. 181-182, pp. 35–38, 2002.
[2] A. M. Di Bisceglie, L. H. Simpson, M. T. Lotze, and J. H. Hoofnagle, “Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection,” Journal of Clinical Gastroenterology, vol. 19, no. 3, pp. 222–226, 1994.
[3] M. C. Hollstein, C. P. Wild, F. Bleicher et al., “p53 mutations and aflatoxin B 1 exposure in hepatocellular carcinoma patients from Thailand,” International Journal of Cancer, vol. 53, no. 1, pp. 51–55, 1993.
[4] S. Y. Kuang, S. Lekawanvijit, N. Maneekarn et al., “Hepatitis B 1762 T /1764 A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 2, pp. 380–384, 2005.
[5] S. Songsivilai, T. Dharakul, and D. Kanistanon, “Hepatitis C virus genotypes in patients with hepatocellular carcinoma and cholangiocarcinoma in Thailand,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 90, no. 5, pp. 505–507, 1996.
[6] P. Tangkijvanich, P. Hirsch, A. Theamboonlers, I. Nuchpray- oon, and Y. Poovorawan, “Association of hepatitis viruses with hepatocellular carcinoma in Thailand,” Journal of Gastroenterology, vol. 34, no. 2, pp. 227–233, 1999.
[7] L. Thaikruea, S. Thongsawat, N. Maneekarn, D. Netski, D. L. Thomas, and K. E. Nelson, “Risk factors for hepatitis C 